Literature DB >> 20082636

Alternative splicing: role of pseudoexons in human disease and potential therapeutic strategies.

Ashish Dhir1, Emanuele Buratti.   

Abstract

What makes a nucleotide sequence an exon (or an intron) is a question that still lacks a satisfactory answer. Indeed, most eukaryotic genes are full of sequences that look like perfect exons, but which are nonetheless ignored by the splicing machinery (hence the name 'pseudoexons'). The existence of these pseudoexons has been known since the earliest days of splicing research, but until recently the tendency has been to view them as an interesting, but rather rare, curiosity. In recent years, however, the importance of pseudoexons in regulating splicing processes has been steadily revalued. Even more importantly, clinically oriented screening studies that search for splicing mutations are beginning to uncover a situation where aberrant pseudoexon inclusion as a cause of human disease is more frequent than previously thought. Here we aim to provide a review of the mechanisms that lead to pseudoexon activation in human genes and how the various cis- and trans-acting cellular factors regulate their inclusion. Moreover, we list the potential therapeutic approaches that are being tested with the aim of inhibiting their inclusion in the final mRNA molecules.

Entities:  

Mesh:

Year:  2010        PMID: 20082636     DOI: 10.1111/j.1742-4658.2009.07520.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  47 in total

1.  Deep Intronic Mutation in SERPING1 Caused Hereditary Angioedema Through Pseudoexon Activation.

Authors:  Pavla Hujová; Přemysl Souček; Lucie Grodecká; Hana Grombiříková; Barbora Ravčuková; Pavel Kuklínek; Roman Hakl; Jiří Litzman; Tomáš Freiberger
Journal:  J Clin Immunol       Date:  2020-01-25       Impact factor: 8.317

Review 2.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

Review 3.  Pre-mRNA splicing in disease and therapeutics.

Authors:  Ravi K Singh; Thomas A Cooper
Journal:  Trends Mol Med       Date:  2012-07-18       Impact factor: 11.951

Review 4.  Antisense mediated splicing modulation for inherited metabolic diseases: challenges for delivery.

Authors:  Belen Pérez; Lluisa Vilageliu; Daniel Grinberg; Lourdes R Desviat
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

Review 5.  Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.

Authors:  Helen L Storr; Sumana Chatterjee; Louise A Metherell; Corinne Foley; Ron G Rosenfeld; Philippe F Backeljauw; Andrew Dauber; Martin O Savage; Vivian Hwa
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

Review 6.  Deep intronic mutations and human disease.

Authors:  Rita Vaz-Drago; Noélia Custódio; Maria Carmo-Fonseca
Journal:  Hum Genet       Date:  2017-05-12       Impact factor: 4.132

Review 7.  Normal and altered pre-mRNA processing in the DMD gene.

Authors:  Sylvie Tuffery-Giraud; Julie Miro; Michel Koenig; Mireille Claustres
Journal:  Hum Genet       Date:  2017-06-09       Impact factor: 4.132

8.  Old gene, new phenotype: splice-altering variants in CEACAM16 cause recessive non-syndromic hearing impairment.

Authors:  Kevin T Booth; Kimia Kahrizi; Hela Azaiez; Richard Jh Smith; Hossein Najmabadi
Journal:  J Med Genet       Date:  2018-04-27       Impact factor: 6.318

9.  Detailed molecular characterization of a novel IDS exonic mutation associated with multiple pseudoexon activation.

Authors:  L Grodecká; T Kováčová; M Kramárek; S Seneca; K Stouffs; C De Laet; F Majer; T Kršjaková; P Hujová; K Hrnčířová; P Souček; W Lissens; E Buratti; Tomas Freiberger
Journal:  J Mol Med (Berl)       Date:  2016-11-12       Impact factor: 4.599

10.  Exonic mutations and exon skipping: Lessons learned from DFNA5.

Authors:  Kevin T Booth; Hela Azaiez; Kimia Kahrizi; Donghong Wang; Yuzhou Zhang; Kathy Frees; Carla Nishimura; Hossein Najmabadi; Richard J Smith
Journal:  Hum Mutat       Date:  2018-01-11       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.